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Introduction {#sec1}
============

During early tumorigenesis, oncogene-driven unscheduled DNA replication causes replication stress (RS), a state characterized by slowed or stalled replication forks, increased single-stranded DNA (ssDNA) and activation of the DNA damage response (DDR) ([@bib7]; [@bib35]). DDR signaling acts as an inducible barrier to cancer progression, setting up a selective pressure for tumors to bypass the DDR. Unscheduled S-phase entry can generate an environment where nucleotides, replication factors, or histones are limiting ([@bib9]; [@bib40]; [@bib59]). Oncogenes can also induce the firing of replication origins within highly transcribed genes, leading to replication-transcription conflicts that can drive chromosomal rearrangements ([@bib53]; [@bib71]).

Tumor cells with high levels of chromosomal instability (CIN) and RS depend on the ATM and RAD3-related(ATR) and Checkpoint kinase 1 (CHK1) kinases to maintain CIN and RS at sub-toxic levels ([@bib74]; [@bib94]). The dynamic maintenance of chromatin structure is required to maintain both genome and epigenome stability, and it regulates cell fate determination ([@bib1]; [@bib98]). ATR/CHK1-mediated DDR signaling is linked to the maintenance of chromatin structure through regulation of tousled-like kinase (TLK) activity ([@bib38]; [@bib54]). The TLKs, TLK1 and TLK2, are conserved Ser-Thr kinases that are critical for regulation of ASF1A and ASF1B, histone H3/H4 chaperones with key roles in histone deposition during DNA replication, DNA repair, and transcription ([@bib12]; [@bib41]; [@bib80]; [@bib85]; [@bib87]; [@bib88]). Depletion of both ASF1A and ASF1B results in replication fork arrest in the absence of ssDNA generation or RS signaling, even in cells treated with the ribonucleotide reductase inhibitor hydroxyurea (HU), which normally induces high levels of RS ([@bib39]).

Depletion of total ASF1 induces features of alternative lengthening of telomeres (ALT), a telomerase-independent, recombination-based telomere maintenance mechanism used in 10%--15% of tumors ([@bib48]; [@bib77]). ALT+ tumors are frequently characterized by inactivation of the Alpha thalassemia/mental retardation syndrome X-linked (ATRX)-Death-domain associated protein (DAXX) complex, which controls histone H3.3 deposition and maintenance of pericentromeric and telomeric heterochromatin. ASF1 facilitates H3.3 deposition through the Histone Cell Cycle Regulation Defective Homolog A (HIRA) or Chromatin Assembly Factor 1 (CAF1) chaperones and may compensate for a lack of ATRX-DAXX in ALT+ tumors ([@bib20]; [@bib65]; [@bib70]).

In cancer cells, defective chromatin assembly caused by ASF1B depletion limits proliferation, and high ASF1B levels correlate with poor patient outcome in breast cancer ([@bib23]). Similarly, TLKs are critical for nucleosome assembly during DNA synthesis and replication fork stability, but in contrast to ASF1 depletion, that arrests forks without provoking ssDNA accumulation, TLK loss leads to acute RS, with increased levels of ssDNA and DNA double-strand breaks (DSBs) ([@bib39]; [@bib59]). Both *TLK1* and *TLK2* are maintained in most cancers and often amplified. In some cases, their increased expression correlates with poor prognosis, suggesting they may be potential cancer targets ([@bib52]; [@bib59]).

DNA damage inducing chemotherapy elicits an inflammatory response involving the induction and secretion of cytokines ([@bib61]; [@bib84]). This relies on the detection of cytosolic DNA by Cyclic GMP-AMP Synthase (cGAS) and Stimulator of Interferon Reponse cGAMP Interactor 1 (STING) signaling. Several nuclease activities, including TREX1, SAMHD1, and MRE11, were implicated in suppression of the interferon (IFN) response ([@bib79]). SAMHD1 localizes to replication forks where it recruits the MRE11 nuclease to regulate replication fork progression and prevent IFN activation in response to RS ([@bib22]). In addition to the so-far poorly defined substrates generated at replication forks, both micronuclei---which can result from RS---and extrachromosomal telomeric repeats (ECTRs) that are produced in ALT+ cancer cells---such as partially single-stranded C-rich telomeric circles (C-circles)---are inducers of cGAS-STING signaling ([@bib17]; [@bib42]; [@bib72]).

We previously demonstrated that TLK depletion impaired *de novo* histone deposition and led to RS ([@bib59]). To understand the genome-wide impact of TLK depletion, we conducted the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and RNA sequencing (RNA-seq) to examine chromatin accessibility and transcription. We found that TLK loss increased chromatin accessibility at heterochromatic regions and caused spurious transcription of silenced repetitive elements and telomeres. In ALT+ U-2-OS cells and in ALT− HeLa LT cells, TLK depletion hyperactivated or induced hallmarks of ALT, respectively, and robustly activated cGAS-STING-TBK1-mediated innate immune responses. Innate immune responses were attenuated by limiting the production of ECTRs but not by modulating RS signaling. Finally, we show that *TLK2* expression correlates with CIN and anti-correlates with innate and adaptive immune responses in many human tumors, suggesting that high TLK levels may prevent innate immune responses induced by CIN and ALT, thus limiting immune recognition in cancer.

Results {#sec2}
=======

Loss of TLK Activity Compromises Heterochromatin Maintenance {#sec2.1}
------------------------------------------------------------

Given that TLK depletion reduced *de novo* histone deposition and provoked RS ([@bib59]), we sought to determine if particular genomic regions may be hypersensitive to TLK1/2 depletion. To map genome-wide effects of TLK depletion on chromatin accessibility, we used the ATAC ([@bib10]) followed by deep sequencing (ATAC-seq) or quantitative real-time PCR (ATAC-qPCR). We evaluated chromatin accessibility in U-2-OS, following depletion of TLK1, TLK2, or both TLK1 and TLK2. To identify relative chromatin accessibility changes, we considered consensus peaks as those present in at least one of four biological conditions ([Figure 1](#fig1){ref-type="fig"}A). From consensus peaks covering the annotated genome, 10% of the genome exhibited differential accessibility upon TLK1/2 depletion ([Figure 1](#fig1){ref-type="fig"}B). These significant changes involved regions depleted of accessible peaks (negative fold change \[FC\]); mainly promoter-transcriptional start site (TSS) regions; and regions enriched with accessible peaks (positive FC), which were mainly intronic and intergenic ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). Single depletion of TLK1 or TLK2 caused similar trends, but differences were more evident following depletion of both ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1Loss of TLK Activity Compromises Heterochromatin Maintenance(A) Schematic depicting experimental design of ATAC experiments in U-2-OS.(B) Chromatin accessibility changes in U-2-OS upon TLK depletion are statistically significant in 10% of the genome (n = 2) (left panel). Genome annotation of peaks with statistically significant negative (2559 peaks) or positive (2941 peaks) FC upon TLK depletion (right panel). See [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} for additional information.(C) Representative Integrative Genomics Viewer (IGV) tracks of ATAC-seq reads of an intronic region (top panel) and intergenic region (bottom panel) that become more accessible upon TLK loss.(D) Boxplots of ATAC-seq FC (siTLK1+2 relative to siCont) through different ChromHMM states.(E) Boxplots of ATAC-seq FC relative to siCont computed in regions that do or do not overlap with H3K9me3 chromatin immunoprecipitation sequencing (ChIP-seq) (GEO: [GSM788078](ncbi-geo:GSM788078){#interref280}).(F) Heatmap of the correlation relationship grouped using hierarchical clustering between ATAC-seq FC (relative to siCont) and large-scale chromatin features at 10-kb resolution.(G) ATAC-qPCR analysis of open chromatin at selected genomic regions in U-2-OS. Data of quantitative real-time PCR amplification are normalized to RNA Pol II promoter region and represented relative to the signal obtained in siCont, which was set to 1 (n = 2).(H) Representative IF images of HP1α staining in U-2-OS (left panel). High-throughput microscopy (HTM) quantification of chromatin-bound HP1α levels (right panel). Data are from one biological replicate with n \>300 nuclei analyzed and are representative of three biological replicates. Median is shown in red.(I) Schematic depicting experimental design of ATAC experiments in HeLa LT.(J) Genome annotation of peaks with statistically significant negative (586 peaks for siCont, 70 peaks for siTLK2) or positive (105 peaks for siCont, 137 peaks for siTLK2) FC upon TLK1/2 loss (n = 2).(K) ATAC-qPCR at selected genomic regions in HeLa LT as in (G) (n = 2).(L) Boxplots depicting ATAC-seq FC relative to siCont computed in regions that do or do not overlap with H3K9me3 ChIP-seq (GEO: [GSM788078](ncbi-geo:GSM788078){#interref285}).^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test with Welch's correction (H), unpaired t test (G and K).

We focused further analysis on regions that became more accessible, as this could reflect defective chromatin assembly ([Figure 1](#fig1){ref-type="fig"}C). To evaluate how accessibility changes correlated with genomic and epigenomic features, we correlated our FCs with chromatin states using the ChromHMM tool ([@bib31]) and observed heterochromatin (constitutive heterochromatin defined as repetitive/copy number variation \[CNV\]) had the most prominent increase in accessibility upon TLK1/2 loss ([Figure 1](#fig1){ref-type="fig"}D). Consistently, ATAC peaks overlapping with H3K9me3, a heterochromatin marker, were enriched upon TLK1/2 depletion ([Figure 1](#fig1){ref-type="fig"}E). At a 10-kb resolution, increased accessibility in TLK1/2-depleted cells positively correlated with H3K9me3 and negatively correlated with the euchromatin mark H3K36me3 and early replication timing ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}D). At this resolution, we did not observe any correlation with chromosomal locations, including distance to telomeres or centromeres ([Figure 1](#fig1){ref-type="fig"}F). Validation by ATAC-qPCR of some high-FC heterochromatic peaks (hit 1 to hit 3), as well as telomeres, confirmed increased accessibility upon TLK loss ([Figures 1](#fig1){ref-type="fig"}C and 1G). This was phenocopied by ASF1 depletion, pointing to defective chromatin assembly as the underlying cause ([Figure S1](#mmc1){ref-type="supplementary-material"}E). To determine if TLK1/2 depletion had a general impact on heterochromatin maintenance, we examined chromatin-bound HP1α, a marker of pericentric heterochromatin, and observed a strong reduction in HP1α signal following TLK depletion ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}F).

As U-2-OS cells are ALT+ and lack ATRX, we considered that they could be more dependent upon TLK-ASF1 for H3.3 deposition required for heterochromatin maintenance ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}F) ([@bib95]). We evaluated chromatin accessibility in HeLa long telomere (LT) cells, a clone of HeLa 1.2.11 derived with LTs of about 20 kb ([Figure 1](#fig1){ref-type="fig"}I) ([@bib77]) and found that while only 1%--3% of consensus peaks displayed statistical significance, the genomic annotation pattern of peaks enriched or depleted upon TLK loss was very similar to U-2-OS ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}G). We validated hit regions and telomeres by ATAC-qPCR in HeLa LT cells ([Figures 1](#fig1){ref-type="fig"}K and [S1](#mmc1){ref-type="supplementary-material"}H) and noted that ATAC peaks overlapping with H3K9me3 marks were enriched in ΔTLK1 siTLK2 samples ([Figure 1](#fig1){ref-type="fig"}L). Overall, these results revealed that constitutive heterochromatin, which is restricted mainly to gene-poor regions, pericentromeres, and telomeres, is most dependent on TLK activity for maintenance. Moreover, our findings imply that ALT+ U-2-OS cells, lacking ATRX, may be particularly dependent on TLK activity for chromatin maintenance.

TLK Activity Suppresses Telomeric Recombination {#sec2.2}
-----------------------------------------------

ALT telomeres in *ATRX*^−/−^ cells are characterized by a reduced occupancy of H3.3-containing nucleosomes ([@bib34]; [@bib63]). H3.3 is required for establishing H3K9me3 and heterochromatin formation, and its absence generates DNA damage and increases telomeric sister chromatid exchange in mouse embryonic stem cells ([@bib95]). Consistent with a decrease in *de novo* histone deposition in TLK-depleted cells ([@bib59]), occupancy of H3.3 was reduced in most genomic locations ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In the absence of TLKs, H3.3 and H3K9me3 occupancy was decreased at telomeres, and transcription of telomeric repeat-containing RNA (TERRA) was elevated ([Figures 2](#fig2){ref-type="fig"}A and 2B), suggestive of potential hyper-recombination at these sites.Figure 2TLK Activity Suppresses Telomeric Recombination(A) ChIP-qPCR analysis of H3.3 and H3K9me3 occupancy at telomeres in U-2-OS. Data of quantitative real-time PCR amplification are normalized to input (n = 2). ChIP-seq data are provided in [Table S3](#mmc4){ref-type="supplementary-material"}.(B) Expression of 15q TERRA by quantitative real-time PCR in U-2-OS normalized to B-actin expression levels. The signal obtained in siCont was set to 1 (n = 2 for RT primer "TERRA," n = 4 for RT primer "Random").(C) IF-FISH staining of chromatin-bound RPA and telomeres in U-2-OS.(D) Representative IF of APBs in U-2-OS. White arrowheads indicate TRF2-PML co-localization.(E) APB quantification in U-2-OS scored as cells with more than five TRF2-PML colocalizing foci, with \>100 cells scored per individual experiment (n = 5 for siCont, n = 4 for siTLK2, n = 3 for ΔTLK1 siCont/siTLK2).(F) HTM quantification of chromatin-bound PML nuclear intensity in U-2-OS. Data are from one biological replicate with n \>180 nuclei analyzed and are representative of four biological replicates. Representative images are shown. Median is shown in red.(G) Quantification of telomeric C-circles in U-2-OS 48 h after siRNA treatment. Telomeric signal was normalized by Alu signal (n = 3). Representative slot blot is shown in the right panel.(H) APB quantification in HeLa LT, scored as in (E), with \>100 cells scored per individual experiment (n = 3).(I) HTM quantification of chromatin-bound PML nuclear intensity in HeLa LT. Data are from one biological replicate with \>100 nuclei analyzed and are representative of three biological replicates. Median is shown in red.(J) Western blot of RS and DDR signaling markers upon TLK2 depletion in HeLa LT WT and ΔTLK1.(K) Representative IF of RPA-TRF2 staining in HeLa LT.(L) Quantification of cells with more than five RPA discrete foci, with \>200 cells evaluated per individual experiment (n = 6 siCont, n = 5 siTLK2, n = 2 ΔTLK1\#5 and ΔTLK1\#12, n = 4 ΔTLK1\#8).(M) Quantification of telomeric C-circles in HeLa LT WT or ΔTLK1 72 h after siRNA treatment. Telomeric signal was normalized by Alu signal (n = 7 siCont, n = 6 siTLK2). Representative slot blot shown in the right panel.^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test with Welch's correction (F and I), unpaired t test (A, B, E, H, and L), unpaired t test, one-tailed (G and M).

We further investigated the relationship between RS signaling and telomeres in U-2-OS cells. Nearly all Replication protein A (RPA) accumulated in discrete foci co-staining with the shelterin subunit TRF2 or telomeric fluorescence *in situ* hybridization (FISH) signal upon TLK depletion ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). Increased RPA accumulation at telomeres suggested exposure of telomeric ssDNA. TLK2 or total TLK depletion in U-2-OS cells caused increased numbers of ALT-associated Promyelocytic Leukemia (PML) bodies (APBs), membrane-free compartments that co-stain with TRF2 and PML where ALT-dependent telomere recombination takes place ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S2](#mmc1){ref-type="supplementary-material"}D) ([@bib48]). Additionally, a remarkable increase in PML body intensity suggested ALT-associated telomere clustering ([Figure 2](#fig2){ref-type="fig"}F) ([@bib29]). TLK depletion resulted in a mild but significant increase in C-circles in ALT+ U-2-OS cells, which already generate large numbers of C-circles ([Figure 2](#fig2){ref-type="fig"}G) ([@bib46], [@bib47]).

Since ASF1 depletion induces ALT features in ALT− cell lines ([@bib77]), we examined TLK depletion in HeLa LT cells, which elongate telomeres via telomerase. Total TLK depletion, achieved by TLK2 siRNA in TLK1 knockout clones (ΔTLK1), increased APBs and the intensity of PML bodies ([Figures 2](#fig2){ref-type="fig"}H and 2I). Total TLK loss caused RS and DSBs in these cells, visualized by phosphorylation of RPA at S4/8 and γH2AX ([Figure 2](#fig2){ref-type="fig"}J) and accumulation of chromatin-bound RPA that often co-localized with telomeres ([Figures 2](#fig2){ref-type="fig"}K, 2L, and [S2](#mmc1){ref-type="supplementary-material"}E). To assess recombination at ALT− telomeres, we quantified C-circles and observed a significant increase following loss of both TLKs ([Figure 2](#fig2){ref-type="fig"}M). Together, these data demonstrate that despite causing a RS phenotype not observed with ASF1 depletion, TLK loss phenocopies ASF1 depletion by compromising telomeric chromatin maintenance and inducing features of the ALT pathway.

TLK Depletion Activates Innate Immune Signaling {#sec2.3}
-----------------------------------------------

Aside from telomeres, disruption of heterochromatin by TLK depletion could also affect the silencing of other genomic loci. To address this, we performed RNA-seq with rRNA depletion in U-2-OS so we could analyze mRNA and other RNA species devoid of a poly(A) tail. We analyzed differential RNA expression by aligning to GENCODE-annotated genetic variants ([@bib43]), including protein-coding loci with alternatively spliced variants, noncoding loci, and pseudogenes. From the GENCODE categories, TLK depletion significantly upregulated the expression of antisense RNA and long intergenic noncoding RNA (lincRNA) ([Figure 3](#fig3){ref-type="fig"}A), consistent with TLKs suppressing ncRNA transcription. Alignment of the RNA-seq data to Repbase ([@bib5]) revealed a significant increase in the expression of satellite RNAs and some human endogenous retroviruses (HERVs) upon TLK depletion ([Figure 3](#fig3){ref-type="fig"}B). ATAC-seq data alignment to Repbase confirmed that chromatin accessibility at these repetitive elements was significantly increased in TLK-depleted U-2-OS cells, and these changes were less prominent in HeLa LT ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), likely reflecting ATRX-DAXX status. Using quantitative real-time PCR, we validated the increased expression of several repetitive elements upon TLK depletion in U-2-OS, including satellites and HERVs, whereas other repetitive elements, such as 5S rDNA or Alu, remained unaffected ([Figure 3](#fig3){ref-type="fig"}C).Figure 3TLK Depletion Activates Innate Immune Signaling(A) Boxplots of RNA-seq noncoding expression, such as antisense RNA or lincRNA, relative to siCont (n = 2).(B) Analysis of repetitive RNA expression (RNA-seq, n = 2). FC in RNAs (siTLK1+2 versus siCont) transcribed from different repeat types was ranked from highest to lowest. Horizontal dotted line represents a cut-off of 2 SD from the mean. Repeats enriched more than 2 SD from the mean are labeled, and colors represent the RepeatMasker broad repeat class to which that repeat type belongs.(C) Expression of DNA repetitive elements by quantitative real-time PCR in U-2-OS. Data are normalized to B-actin, and expression in siCont conditions was set to 1 (n = 5 Sat-α/Satellite2/17-alphoid, n = 6 HERV-H, n = 3 HERV-K, n = 4 Alu/5S rDNA).(D) Volcano plot representing gene expression profile of siTLK1+2 versus siCont obtained from RNA-seq in U-2-OS (n = 2). Gray dots indicate genes, and green dots represent the most downregulated genes together with TLK1 and TLK2. Red dots represent genes belonging to the IFN response. The p values and FC are computed by fitting a linear model with the R package limma. See [Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"} for additional data.(E) GO analysis (enrichment biological process) of RNA-seq differentially upregulated genes upon TLK1/2 knockdown.(F) GSEA of RNA-seq positively enriched genes related to innate immunity corresponding to the samples siTLK1+2 versus siCont.(G) GSEA plots of selected differentially expressed gene categories corresponding to the RNA-seq samples siTLK1+2 versus siCont.(H) Validation of expression levels of RNA and DNA sensors and IFN response genes by quantitative real-time PCR in U-2-OS. Data analyzed as in (C) (n = 4).(I) Expression levels of IFN response genes by quantitative real-time PCR in HeLa LT. Data were analyzed as in (C) (n = 3).(J) Expression levels of IFN response genes by quantitative real-time PCR in GM847. Data were analyzed as in (C) (n = 3).(K) CXCL10 concentration was measured in the supernatant of U-2-OS 96 h after siRNA treatment by ELISA (n = 2).^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test, one-tailed (C and H--J).

Analysis of differential gene expression (−Log~2~FC cut-off of 2) revealed that upon TLK loss, more genes were upregulated than downregulated ([Figure 3](#fig3){ref-type="fig"}D), with the strongest change being an innate immune response comprising type-I IFN and tumor necrosis factor alpha (TNF-α) programs. Gene Ontology (GO) analysis confirmed that antiviral responses were the most enriched categories in the upregulated genes ([Figure 3](#fig3){ref-type="fig"}E), and gene set enrichment analysis (GSEA) uncovered that upregulation of IFN response signatures was highly significant in TLK-depleted cells ([Figure 3](#fig3){ref-type="fig"}F). In addition, checkpoint response and apoptosis signatures were upregulated, whereas the E2F target signature was downregulated ([Figure 3](#fig3){ref-type="fig"}G), corroborating p53 activation, G1/S cell cycle arrest, and cell death phenotypes previously reported ([@bib59]). We further validated upregulation of IFN response genes by quantitative real-time PCR in U-2-OS cells and in two additional cell lines, ALT+ GM847 and ALT− HeLa LT ([Figures 3](#fig3){ref-type="fig"}H--3J, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). Notably, numerous genes that recognize viral RNAs were upregulated, including *MDA5/IFIH1*, *RIG-I/DDX58*, and *TLR3*, as well as *STING/TMEM173*, an important mediator in response to cytosolic DNA detected by cGAS. These were accompanied by a number of other IFN-stimulated genes, including *IFI6*, *ISG15*, *IFIT2*, *OASL*, *DDX60*, *CXCL10*, and *RSAD2* ([Figures 3](#fig3){ref-type="fig"}H--3J). To assess whether the transcriptional induction of innate immune genes resulted in pro-inflammatory cytokine secretion, we measured CXCL10/IP-10 protein in the cellular supernatant by ELISA and found increased levels upon TLK depletion ([Figure 3](#fig3){ref-type="fig"}K).

Innate Immune Activation Is Dependent on the cGAS-STING-TBK1 Axis {#sec2.4}
-----------------------------------------------------------------

RS, ERVs, and ECTRs have all been implicated in innate immune activation. We next examined the molecular trigger for upregulation of *RSAD2* and *STING* after TLK depletion. Depletion of STING in HeLa LT cells severely reduced *RSAD2* induction without impacting RS signaling, thus implicating the cGAS-STING pathway ([Figures 4](#fig4){ref-type="fig"}A and 4B). Many ALT+ tumor cell lines, including U-2-OS, epigenetically silence STING, presumably to prevent the activation of innate immunity through cGAS sensing of ECTRs ([@bib6]; [@bib17]; [@bib96]; [@bib97]). We observed increased mRNA and protein levels of STING, as well as *RSAD2* induction in ALT+ U-2-OS cells ([Figures 3](#fig3){ref-type="fig"}H and [4](#fig4){ref-type="fig"}C). Canonical STING activation induces type-I IFN genes through TBK1 and the transcription factor IRF3, acting primarily in response to production of 2′3′-cGAMP by cGAS, following dsDNA recognition ([@bib16]). Both HeLa LT and U-2-OS cells increased 2′3′-cGAMP production after TLK depletion to a similar extent as controls transfected with a dsDNA90 molecule ([Figures 4](#fig4){ref-type="fig"}D and 4E). Treatment of U-2-OS cells with a TBK1 inhibitor (BX795) completely abolished the upregulation of *RSAD2*, but not *STING*, following TLK depletion ([Figure 4](#fig4){ref-type="fig"}F). Knockout of cGAS using an inducible Cas9 (iCas9) system in U-2-OS similarly did not influence *STING* levels but impaired activation of *RSAD2*, *OASL*, and *IFIT2* ([Figures 4](#fig4){ref-type="fig"}G, 4H, and [S4](#mmc1){ref-type="supplementary-material"}A). These results suggested that STING reactivation occurred through desilencing, rather than by cGAS-mediated pathways. Consistent with this, increased accessibility of the STING promoter was detected in TLK-depleted U-2-OS cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 4Innate Immune Activation Is Dependent on the cGAS-STING-TBK1 Axis(A) Western blot of HeLa LT infected with scramble shRNA or shRNA against STING, 48 h after siRNA treatment.(B) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in HeLa LT 48 h after siRNA treatment. Data are normalized to B-actin and siCont signal set to 1 (n = 3).(C) Western blot of STING in U-2-OS cells, 48 h after siRNA treatment.(D) 2′3′-cGAMP production ELISA analysis in HeLa LT 72 h after siRNA treatment. Transfection with dsDNA90 24 h prior to harvesting is included as a positive control (n = 4 for siRNA, n = 2 for dsDNA90).(E) 2′3′-cGAMP production analyzed by ELISA in U-2-OS treated as in (D) (n = 3 for siRNA, n = 2 for dsDNA90).(F) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in U-2-OS mock treated or treated with 1 μM BX795 for 24 h. Data analyzed as in (B) (n = 2).(G) Western blot showing cGAS knockout and TLK depletion in U-2-OS iCas9 cells. Ponceau staining shown as a loading control.(H) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in U-2-OS iCas9 72 h after knockout induction and 48 h after siRNA treatment. Data analyzed as in (B) (n = 3).(I) Western blot showing cGAS/RIG-I/MDA5 knockouts and TLK depletion in U-2-OS iCas9 120 h after knockout induction and 96 h after siRNA treatment. Ponceau staining shown as a loading control.(J) CXCL10 concentration measured in the supernatant of U-2-OS iCas9 cells by ELISA (n = 3).^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test (B, D, and F--H), two-way ANOVA (J).

In addition to cGAS, RIG-I and MDA5, which were both upregulated following TLK depletion ([Figures 3](#fig3){ref-type="fig"}D and 3H), sense distinct RNA species that trigger their interactions with Mitochondrial Antiviral Signaling Protein (MAVS) to activate IFN signaling ([@bib99]). Given the increased transcription of ncRNA observed upon TLK depletion ([Figures 3](#fig3){ref-type="fig"}A--3C) and that MAVS and STING interact ([@bib49]; [@bib102]), we examined their influence on *STING* and *RSAD2* induction. Unlike cGAS, neither RIG-I nor MDA5 knockout impaired *RSAD2* activation upon TLK depletion. STING reactivation also occurred regardless of RIG-I or MDA5 status ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4F), indicating they did not influence the response at either level. Finally, we confirmed that CXCL10 secretion was also dependent on cGAS, but not RIG-I or MDA5, following TLK depletion ([Figures 4](#fig4){ref-type="fig"}I and 4J). Collectively, these data demonstrate that the cGAS-STING-TBK1 pathway promotes innate immune activation in TLK1/2-depleted cells, and STING reactivation occurs independently of the dsDNA sensor cGAS or the RNA sensors RIG-I and MDA5.

Innate Immune Activation Is Independent of RS {#sec2.5}
---------------------------------------------

We previously demonstrated that H3/H4 deposition was impaired in TLK-depleted cells and strongly dependent upon active DNA replication, when the highest levels of histone exchange occur ([@bib59]). Similarly, we found that innate immune activation upon TLK loss was strongly reduced following serum starvation or treatment of cells with the CDK2 inhibitor Roscovitine ([Figures 5](#fig5){ref-type="fig"}A and 5B). RS has been implicated in innate immune activation, particularly through SAMHD1 promotion of MRE11-mediated resection of stalled forks ([@bib22]). The depletion of SAMHD1 mitigated RS and DSBs in TLK-depleted U-2-OS cells ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}A). However, the activation of both *RSAD2* and *STING* was unaffected by SAMHD1 loss following TLK depletion ([Figure 5](#fig5){ref-type="fig"}D). Depletion of MRE11 by siRNA or its inhibition with Mirin also attenuated RS signaling ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). This partially alleviated *RSAD2* and, to a lesser extent, *STING*, although impairing MRE11 may have stronger effects on cell cycle progression than SAMHD1 depletion ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Treatment of U-2-OS cells with HU to induce RS did not activate *STING* or *RSAD2* expression per se in various cell lines, with the exception of RPE-1 cells ([Figures 5](#fig5){ref-type="fig"}E, 5F, and [S5](#mmc1){ref-type="supplementary-material"}D--S5F). Notably, STING protein levels remained low in HU-treated U-2-OS cells ([Figure 5](#fig5){ref-type="fig"}E). In addition, *STING* and *RSAD2* activation following TLK depletion were not consistently enhanced by HU or aphidicolin (APH) in U-2-OS or HeLa LT ([Figures 5](#fig5){ref-type="fig"}F, [S5](#mmc1){ref-type="supplementary-material"}E, and S5F). While micronuclei were induced 2-fold by TLK depletion, they also did not correlate with RS levels ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H). These data indicate that attenuation (SAMHD1 depletion) or enhancement (HU) of RS signaling induced by TLK depletion does not influence innate immune induction. Conversely, cell cycle progression promotes the response, suggesting that replication-coupled histone loss drives innate immune signaling following depletion of TLK1/2.Figure 5Innate Immune Activation Is Independent of RS(A) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in control or serum-starved U-2-OS 48 h after siRNA treatment. Data are normalized to B-actin and siCont expression set to 1 (n = 2).(B) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in U-2-OS mock-treated or treated with 50 μM Roscovitine for 5 h. Data analyzed as in (A) (n = 5).(C) Western blot showing single or double depletion of TLKs and SAMHD1 in U-2-OS harvested 48 h after siRNA treatment. Ponceau staining shown as a loading control.(D) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in U-2-OS 48 h after siRNA treatment. Data analyzed as in (A) (n = 3).(E) Western blot in U-2-OS 48 h after siRNA transfection mock-treated or with 2 mM HU for 2 h. Ponceau staining shown as a loading control.(F) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in U-2-OS mock-treated or treated with 0.5 mM HU for 2 h or 0.5 μM aphidicolin for 4 h. Data analyzed as in (A) (n = 2).^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test (A, B, D, and F).

ALT Contributes to Innate Immune Induction Following TLK Depletion {#sec2.6}
------------------------------------------------------------------

To determine if ALT could be a major driver of innate immunity in TLK-depleted cells, we examined the influence of the Bloom syndrome protein (BLM) helicase on C-circle production in HeLa LT cells. BLM is required for resection by DNA2/EXO1, as well as for dissolution of ALT recombination intermediates as part of the BLM, TOP3a, RMI1, and RMI2 (BTR) complex ([@bib15]; [@bib36]; [@bib75]; [@bib78]; [@bib89]). BLM depletion strongly attenuated C-circles and reduced *STING* and *RSAD2* induction in HeLa LT cells following TLK depletion ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). We next examined U-2-OS cells lacking PML, a key component of APBs that is required for efficient C-circle production ([Figure 6](#fig6){ref-type="fig"}C) ([@bib68]). Deletion of PML also strongly attenuated *RSAD2* induction following TLK1/2 depletion and reduced extranuclear telomeric FISH signal, indicating that ECTR production contributes to innate immune activation in TLK-depleted cells ([Figures 6](#fig6){ref-type="fig"}D, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C). Notably, TLK depletion mildly upregulated C-circle production in ALT+ U-2-OS, which already produces high levels of C-circles ([Figures 2](#fig2){ref-type="fig"}G and [6](#fig6){ref-type="fig"}C), but strongly upregulated *RSAD2* through reactivation of STING ([Figure 4](#fig4){ref-type="fig"}C). As these results implicated C-circles in innate immune signaling following TLK depletion, we examined the ability of the fusion protein TRF1-FokI, which generates telomeric breaks that undergo break-induced telomere synthesis and produces C-circles in a BLM/PML-independent manner ([@bib19]; [@bib26]), to induce innate immune signaling in U-2-OS. Expression of TRF1-FokI wild type (WT), but not the nuclease dead (D450A), increased C-circle levels in U-2-OS cells to a similar extent as TLK depletion ([Figures 6](#fig6){ref-type="fig"}E and 6F). However, only TLK-depleted cells activated STING ([Figure 6](#fig6){ref-type="fig"}G), suggesting that epigenetic silencing of STING requires TLK-mediated chromatin maintenance to prevent innate immune activation by ECTRs. Together, we found that the production of C-circles following TLK loss triggers the activation of cGAS-STING-TBK1-mediated innate immune responses. Additionally, in cells where STING is silenced, a first-tier reactivation at the epigenetic level is required to fully promote this IFN response.Figure 6ALT Induction Contributes to Innate Immunity Following TLK1/2 Depletion(A) Telomeric C-circle quantification in HeLa LT. TelC signal was normalized by Alu signal (n = 2). Representative slot blot shown in top panel.(B) Expression levels of *STING* and *RSAD2* by quantitative real-time PCR in HeLa LT cells 48 h after treatment with corresponding siRNAs. Data are normalized to B-actin and siCont expression set to 1 (n = 2).(C) Telomeric C-circle quantification in U-2-OS. TelC signal was normalized by Alu signal (n = 3). Representative slot blot shown in top panel.(D) Expression levels of *RSAD2* by quantitative real-time PCR in U-2-OS 48 h after siRNA treatment. Data analyzed as in (B) (n = 4).(E) Western blot showing TLK depletion and TRF1-FokI expression in U-2-OS 48 h after siRNA and 24 h after TRF1-FokI transfection. Ponceau staining shown as a loading control.(F) Telomeric C-circle quantification in U-2-OS expressing TRF1-FokI. TelC signal was normalized by Alu signal (n = 3). Representative slot blot shown in left panel.(G) Expression levels of *STING* by quantitative real-time PCR in U-2-OS cells treated as in (E). Data analyzed as in (B) (n = 3).^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05; unpaired t test (A--D and G).

TLK Expression Correlates with Suppressed Innate Immune Signaling in Human Cancer {#sec2.7}
---------------------------------------------------------------------------------

Tumors with unstable genomes, micronuclei, and ALT+ telomeres generate sources of immunostimulation that can induce an IFN response and often circumvent this pathway by silencing STING epigenetically to minimize immune surveillance ([@bib3]; [@bib17]; [@bib96]). We next analyzed publicly available datasets from The Cancer Genome Atlas (TCGA) for correlations among *TLK1* and *TLK2* levels, chromosomal instability, and immunity across different tumor types. Expression levels of *TLK1* and *TLK2* anti-correlated significantly with STING (encoded by the *TMEM173* gene) in many tumor types ([Figures 7](#fig7){ref-type="fig"}A and 7B). We reasoned that tumors with high levels of genome instability may select for STING silencing and higher levels of TLK activity to suppress toxic RS. We examined CIN levels in tumors by using a previously defined signature containing a 25-gene set ([@bib13]), as well as the aneuploidy score estimated from comparative genomic hybridization (CGH) SNP arrays, a measure independent of gene expression ([@bib92]). While *TLK1* expression levels only positively correlated with CIN/aneuploidy levels in selected tumor types, *TLK2* expression significantly correlated with CIN/aneuploidy levels in most tumor types ([Figure 7](#fig7){ref-type="fig"}B).Figure 7TLK Expression Correlates with Suppressed Innate Immune Signaling in Human Cancer(A) Correlation between *TLK1/TLK2* and STING (*TMEM173*) in the TCGA datasets of low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD).(B) Heatmaps with correlations of expression levels of *TLK1* and *TLK2* with CIN signature, aneuploidy score, STING (*TMEM173*), and signatures of tumor-immune populations across different TCGA datasets. Stars indicate adjusted p values for multiple comparisons using Benjamini-Hochberg (^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05).(C) Boxplot of expression levels of genes, CIN signature, aneuploidy score, and different signatures of tumor-immune populations. Analysis was performed in different merged TCGA datasets where TMM status was defined. Stars indicate adjusted p values for multiple comparisons using Benjamini-Hochberg (^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05).(D) Model of how TLK activity maintains heterochromatin state and its loss promotes spurious transcription and telomere recombination, triggering an innate immune response.

Following these correlations, we next addressed whether TLK2^high^-STING^low^-CIN^high^ tumors were differentially infiltrated by immune cell populations. We took measurements of leukocyte and stromal fractions based on methylation and expression signatures ([@bib92]) and detected several tumor types with significantly reduced fractions of immune infiltration correlating with high TLK expression ([Figure 7](#fig7){ref-type="fig"}B). Interestingly, some of the tumor types with this behavior are described to be immune infiltration depleted or "cold" tumors such as low-grade glioma (LGG), adrenocortical carcinoma (ACC), liver hepatocellular carcinoma (LIHC), glioblastoma multiforme (GBM), and sarcoma (SARC) ([Figure 7](#fig7){ref-type="fig"}B) ([@bib93]), and several of these tumor types are frequently ALT+ ([@bib14]; [@bib58]). Lastly, we analyzed the relationship between different telomere maintenance mechanisms (TMMs) and the signatures described above. Overall, ALT+ tumors positively correlated with CIN/aneuploidy levels and anti-correlated with signatures of immune infiltration ([Figure 7](#fig7){ref-type="fig"}C). Despite not being significant, potentially due to variability across cancer types and a low number of annotated ALT+ tumors in any given cohort, ALT+ tumors showed a tendency toward higher levels of *TLK2* and lower levels of *STING*. This suggests that tumors that harbor high levels of genome instability (CIN^high^ or ALT+ tumors) may select for high TLK levels and defective cytosolic DNA sensing by STING silencing, as a means to prevent tumor recognition by the immune system.

Discussion {#sec3}
==========

Here, we establish that TLKs play a critical role in chromatin maintenance and, if compromised, result in the induction of a cGAS-STING-TBK1-dependent IFN response, even in cells where STING was epigenetically silenced. TLKs promote heterochromatin maintenance at repetitive genome elements and telomeres, and their depletion results in epigenome instability characterized by spurious transcription of ERVs and ncRNAs and enhanced features of ALT ([Figure 7](#fig7){ref-type="fig"}D). This innate immune response is augmented by DNA replication, reflecting the fact that TLK depletion phenotypes entail passage through S-phase where histone exchange levels are highest, but is not influenced by the intensity of RS signaling per se. The induction of the IFN response in TLK-depleted ALT+ cells is first dependent on STING reactivation and then on stimulation of the pathway through ECTRs generated in a BTR-PML-dependent manner. However, we cannot exclude a potential contribution of RS, micronuclei, ERVs, or reverse-transcribed transcripts to the IFN response ([@bib22]; [@bib25]; [@bib33]; [@bib44]; [@bib83]). Collectively, our results indicate that faulty heterochromatin maintenance and elevated telomeric recombination in TLK-depleted cells lead to the induction of innate immunity.

Activation of cGAS-STING by DNA damage and RS, particularly through the recognition of micronuclei, is well documented ([@bib42]; [@bib55]; [@bib72]). By-products of replication fork processing have been implicated in innate immunity by SAMHD1-MRE11-suppressing IFN response activation following treatment with HU ([@bib22]). We identified a clear separation of function, as SAMHD1 is required for RS signaling but dispensable for innate immune activation following TLK depletion ([Figures 5](#fig5){ref-type="fig"}C and 5D). Elevated RS signaling by HU treatment failed to trigger or increase the IFN response in WT or TLK-depleted cells, suggesting it is not the primary cause. Perturbation of the epigenetic landscape by depleting H3.3, multiple H1 genes, or DNA methylases resulted in transcription of noncoding repeat elements from heterochromatin, similar to what we have observed here following TLK depletion, and this was accompanied by the activation of an antiviral response in some cases ([@bib18]; [@bib30]; [@bib50]). This is the first association of TLK activity with the silencing of endogenous viruses and innate immunity, although TLK2 was identified in a screen for gammaherpesvirus latency, a process that involves both epigenetic mechanisms and interactions with innate immune signaling ([@bib27]; [@bib90]).

ALT+ cells are typically characterized by high levels of CIN and higher basal levels of RS, and they display complex karyotypes ([@bib32]; [@bib73]). In addition, ECTRs generated by ALT induce the cGAS-STING pathway and were proposed to provide selective pressure for the epigenetic silencing of STING to suppress potentially cytostatic innate immune signaling ([@bib17]). ALT+ cells deficient in ATRX may also have a higher dependency on ASF1 and, thus, TLK activity, to support H3.3 deposition and heterochromatin maintenance ([@bib65]; [@bib70]). This is consistent with previous work that showed redundancy in the histone chaperone network that can mitigate deleterious effects arising upon histone pool or histone chaperone imbalances ([@bib28]; [@bib56]). Although TLK activity suppresses ALT, TLK dysfunction is unlikely to be an ALT driver event in cancer, since both *TLK1* and *TLK2* are very rarely mutated or deleted in cancer genomes and are required for DNA replication ([@bib59]). Instead, ALT+ cells may be addicted to and select for TLK activity in order to support heterochromatin maintenance in the absence of ATRX and circumvent innate immune responses.

Our results suggest that reactivation of STING expression in ALT+ cancer cells upon TLK inhibition would be a potential strategy to re-sensitize ALT+ or CIN cells to cytosolic DNA fragments. This inflammatory response may render cancer cells vulnerable to cytotoxic immune cell recruitment and enhance immunotherapy approaches. This is supported by a recent *in vivo* CRISPR/Cas9 screen where ASF1A deletion enhanced the efficacy of PD-1 immunotherapy ([@bib64]), as well as by the use of inhibitors for key regulators of epigenome maintenance, CDK9 and DNMT1 ([@bib101]), and STING agonists as stand-alone agents or in enhancing the effects of immunotherapy ([@bib8]; [@bib24]; [@bib81]). However, IFN responses have also been implicated in promoting metastasis in CIN^high^ tumors, and it is likely that important context-dependent effects of agents that activate STING will need to be considered ([@bib4]).

Taken together, we have uncovered a complex connection among TLK-mediated chromatin maintenance, ALT, and the innate immune response. These results suggest that TLK activity may promote immune suppression in a subset of tumors, and its inhibition could therefore represent a novel rational targeted therapy to render ALT+ or CIN^high^ cancers more vulnerable to the induction of cell death and enhance existing therapies. Moreover, the newly uncovered role of TLK activity in the suppression of innate immunity may be highly relevant to the etiology of intellectual disability/autism spectrum disorder in patients with germline *TLK2* mutations ([@bib60]; [@bib76]; [@bib82]; [@bib86]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-TLK1Cell Signaling TechnologyCat\# 4125; RRID:[AB_2203885](nif-antibody:AB_2203885){#intref0010}Rabbit polyclonal anti-TLK2Bethyl LaboratoriesCat\# A301-257A; RRID:[AB_890676](nif-antibody:AB_890676){#intref0015}Rabbit polyclonal anti-phospho RPA32 (S4/S8)Bethyl LaboratoriesCat\# A300-245A; RRID:[AB_210547](nif-antibody:AB_210547){#intref0020}Rabbit polyclonal anti-phospho RPA32 (S33)Bethyl LaboratoriesCat\# A300-246A; RRID:[AB_2180847](nif-antibody:AB_2180847){#intref0025}Mouse monoclonal anti-RPA32, clone RPA34-20CalbiochemCat\# NA19L; RRID:[AB_565123](nif-antibody:AB_565123){#intref0030}Rabbit polyclonal anti-phospho H2AX (S139) (γH2AX)Santa Cruz BiotechnologyCat\# sc-101696; RRID:[AB_2114997](nif-antibody:AB_2114997){#intref0035}Rabbit polyclonal anti-phospho H2AX (S139) (γH2AX)Cell Signaling TechnologyCat\# 2577; RRID:[AB_2118010](nif-antibody:AB_2118010){#intref0040}Rabbit polyclonal anti-phospho p53 (S15)Cell Signaling TechnologyCat\# 9284; RRID:[AB_331464](nif-antibody:AB_331464){#intref0045}Mouse monoclonal anti-MRE11, clone 18Santa Cruz BiotechnologyCat\# sc-135992; RRID:[AB_2145244](nif-antibody:AB_2145244){#intref0050}Rabbit polyclonal anti-BLMAbcamCat\# ab2179; RRID:[AB_2290411](nif-antibody:AB_2290411){#intref0055}Mouse monoclonal anti-STING/TMEM173, clone 723505R&D SystemsCat\# MAB7169; RRID:[AB_10971940](nif-antibody:AB_10971940){#intref0060}Rabbit monoclonal anti-cGAS, clone D1D3GCell Signaling TechnologyCat\# 15102; RRID:[AB_2732795](nif-antibody:AB_2732795){#intref0065}Rabbit monoclonal anti-RIG-I, clone D14G6Cell Signaling TechnologyCat\# 3743; RRID:[AB_2269233](nif-antibody:AB_2269233){#intref0070}Rabbit monoclonal anti-MDA5, clone D74E4Cell Signaling TechnologyCat\# 5321; RRID:[AB_10694490](nif-antibody:AB_10694490){#intref0075}Mouse monoclonal anti-HP1α, clone 2HP1H5Active MotifCat\# 39977; RRID:[AB_2614983](nif-antibody:AB_2614983){#intref0080}Mouse monoclonal anti-PML, clone PG-M3Santa Cruz BiotechnologyCat\# sc-966; RRID:[AB_628162](nif-antibody:AB_628162){#intref0085}Rabbit polyclonal anti-TRF2Novus BiologicalsCat\# NB110-57130; RRID:[AB_844199](nif-antibody:AB_844199){#intref0090}Mouse monoclonal anti-TRF1, clone TRF-78AbcamCat\# ab10579; RRID:[AB_2201461](nif-antibody:AB_2201461){#intref0095}Rabbit polyclonal anti-H3.3EMD MilliporeCat\# 09-838; RRID:[AB_10845793](nif-antibody:AB_10845793){#intref0100}Rabbit polyclonal anti-Histone H3 (tri methyl K9) (H3K9me3)AbcamCat\# ab8898; RRID:[AB_306848](nif-antibody:AB_306848){#intref0105}Goat anti-Mouse IgG (H+L) Secondary Antibody, HRPThermo Fisher ScientificCat\# 31430; RRID:[AB_228307](nif-antibody:AB_228307){#intref0110}Polyclonal Goat Anti-Mouse Immunoglobulins/HRPAgilent-DakoCat\# P0447; RRID:[AB_2617137](nif-antibody:AB_2617137){#intref0115}Polyclonal Swine Anti-Rabbit Immunoglobulins/HRPAgilent-DakoCat\# P0399; RRID:[AB_2617141](nif-antibody:AB_2617141){#intref0120}Alexa Fluor 488 Goat anti-Rabbit IgG (H+L)Thermo Fisher ScientificCat\# A11008; RRID:[AB_143165](nif-antibody:AB_143165){#intref0125}Alexa Fluor 488 Goat anti-Mouse IgG (H+L)Thermo Fisher ScientificCat\# A11001; RRID:[AB_2534069](nif-antibody:AB_2534069){#intref0130}Alexa Fluor 568 Goat anti-Rabbit IgG (H+L)Thermo Fisher ScientificCat\# A11011; RRID:[AB_143157](nif-antibody:AB_143157){#intref0135}Alexa Fluor 568 Goat anti-Mouse IgG (H+L)Thermo Fisher ScientificCat\# A11004; RRID:[AB_2534072](nif-antibody:AB_2534072){#interref295}**Bacterial and Virus Strains**Bacteria: TOP10 Chemically Competent *E. coli*Thermo Fisher ScientificCat\# C404006Lentivirus: pLKO.1-puro-shScramble controlIRB Functional Genomics CoreCat\# SHC002Lentivirus: pLKO.1-puro-shSTINGIRB Functional Genomics CoreCat\# TRCN0000163296**Chemicals, Peptides, and Recombinant Proteins**HydroxyureaSigma-AldrichCat\# H8627AphidicolinCalbiochemCat\# 178273, CAS 38966-21-1RoscovitineTocrisCat\# 1332MirinTocrisCat\# 3190BX-795SelleckchemCat\# S1274Lipofectamine 2000 Transfection ReagentThermo Fisher ScientificCat\# 11668027Lipofectamine RNAiMAX Transfection ReagentThermo Fisher ScientificCat\# 13778150Dynabeads Protein GThermo Fisher ScientificCat\# 10004D4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI)Sigma-AldrichCat\# 32670VECTASHIELD Antifade Mounting MediumVector LaboratoriesCat\# H-1000ProLong Gold Antifade Mountant with DAPIThermo Fisher ScientificCat\# P36935Crystal VioletSigma-AldrichCat\# HT90132phi29 DNA PolymeraseNEBCat\# M0269Lphi29 DNA PolymeraseThermo Fisher ScientificCat\# EP0092ATP, \[γ-32P\]- 6000Ci/mmol 10mCi/mlPerkin ElmerCat\# NEG502Z250UCPhosphatase Inhibitor Cocktail 2Sigma-AldrichCat\# P5726Phosphatase Inhibitor Cocktail 3Sigma-AldrichCat\# P0044cOmplete, EDTA-free Protease Inhibitor CocktailRocheCat\# 04693132001M-PER Mammalian Protein Extraction ReagentThermo Fisher ScientificCat\# 78503T4 Polynucleotide KinaseNEBCat\# M0236SMinElute PCR Purification KitQIAGENCat\# 28004PureLink Quick Gel Extraction & PCR Purification Combo KitThermo Fisher ScientificCat\# K220001Pierce Recombinant Protein A/G, Peroxidase ConjugatedThermo Fisher ScientificCat\# 32490**Critical Commercial Assays**Nextera DNA Library Preparation KitIlluminaCat\# FC-121-1030NEBNext High-Fidelity 2X PCR Master MixNEBCat\# M0541SHigh-Capacity cDNA Reverse Transcription KitThermo Fisher ScientificCat\# 4368814PureLink RNA Mini KitThermo Fisher ScientificCat\# 12183018ARibo-Zero Gold rRNA Removal Kit (Human/Mouse/Rat)IlluminaCat\# RZHM11106NEBNext Ultra II DNA Library Prep Kit for IlluminaNEBCat\# E7645SBD OptEIA Human IP-10 ELISA KitBD BioscienceCat\# 5509262′3′-cGAMP ELISA KitCayman ChemicalCat\# 501700Qubit dsDNA HS Assay KitThermo Fisher ScientificCat\# Q32854Telomere PNA FISH Kit/Cy3Agilent-DakoCat\# K5326TelC-FITCPNA BioCat\# F1009**Deposited Data**Raw and processed data (ATAC-Seq in U-2-OS)This studyGSE131023[Table S1](#mmc2){ref-type="supplementary-material"}Raw and processed data (ATAC-Seq in HeLa LT)This studyGSE131023[Table S2](#mmc3){ref-type="supplementary-material"}Raw and processed data (H3.3 ChIP-Seq in U-2-OS)This studyGSE131023[Table S3](#mmc4){ref-type="supplementary-material"}Raw and processed data (RNA-Seq in U-2-OS)This studyGSE131023[Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}**Experimental Models: Cell Lines**Human: U-2-OSATCCRRID:CVCL_0042Human: HeLa LTGift from J. Jacobs / J. Karlseder[@bib77]Human: GM847Gift from J. LingnerRRID:CVCL_7908Human: RPE-1 hTERTThe Francis Crick Institute Cell ServicesRRID:CVCL_4388Human: AD293StratageneRRID:CVCL_9804Human: HEK293The Francis Crick Institute Cell ServicesRRID:CVCL_0045Human: U-2-OS ΔTLK1This studyN/AHuman: U-2-OS ΔPML clone \#15G4Gift from E. Lazzerini-Denchi[@bib68]Human: HeLa LT ΔTLK1 clone \#5This studyN/AHuman: HeLa LT ΔTLK1 clone \#8This studyN/AHuman: HeLa LT ΔTLK1 clone \#12This studyN/AHuman: U-2-OS iCas9 clone \#5This studyN/A**Experimental Models: Organisms/Strains**N/A**Oligonucleotides**ON-TARGETplus Non-targeting Control PoolDharmaconD-001810-10ON-TARGET plus SMARTpool human TLK1DharmaconL-004174-00ON-TARGET plus SMARTpool human TLK2DharmaconL-005389-00ON-TARGET plus SMARTpool human BLMDharmaconL-007287-00Human SAMHD1_7 FlexiTube siRNAQIAGENCat\# SI04243673siMRE11 (5′-GCUAAUGACUCUGAUGAUA-3′)Thermo Fisher Scientific[@bib106]siTLK1 (5′-GAAGCUCGGUCUAUUGUAA-3′)Thermo Fisher Scientific[@bib59]siTLK2\#1 (5′-GGAGGGAAGAAUAGAUGAU-3′)Thermo Fisher Scientific[@bib59]siTLK2\#2 (5′-GGAAAGGAUAAAUUCACAG-3′)Thermo Fisher Scientific[@bib59]siTLK2\#9 (5′-GAUAGAAAGACAACGGAAA-3′)DharmaconJ-005389-09siASF1a (5′-AAGUGAAGAAUACGAUCAAGU-3′)Thermo Fisher Scientific[@bib59]siASF1b (5′-AACAACGAGUACCUCAACCCU-3′)Thermo Fisher Scientific[@bib59]siH3.3\#A (5′-CUACAAAAGCCGCUCGCAA-3′)Thermo Fisher Scientific[@bib107]siH3.3\#B (5′-GCUAAGAGAGUCACCAUCA-3′)Thermo Fisher Scientific[@bib107]siGL2 (5′-CGUACGCGGAAUACUUCGA-3′)Thermo Fisher Scientific[@bib59]siGFP (5′-GGCUACGUCCAGGAGCGCCGCACC-3′)Thermo Fisher Scientific[@bib59]Guide RNA sequence targeting human TLK1 exon 10 (5′-TAACTGTTGTAAAGTGCCCG-3′)Sigma-AldrichN/AEdit-R tracrRNADharmaconU-002005Edit-R Synthetic crRNA Non-targeting ControlDharmaconU-007503-01Edit-R Human MB21D1/cGAS crRNADharmaconCM-015607-03Edit-R Human DDX58/RIG-I crRNADharmaconCM-012511-01Edit-R Human IFIH1/MDA5 crRNADharmaconCM-013041-01See [Table S6](#mmc7){ref-type="supplementary-material"} for additional oligonucleotides used for ATAC library preparation, RT-qPCR assays, C-circle assay probesSigma-AldrichN/A**Recombinant DNA**pX330-CRISPR-Cas9-SV40prom-EGFPGift from C. Cortina, E. Batlle laboratory[@bib21]pHFUW-Flag-TRF1-FokI WTGift from R. Greenberg[@bib19]pHFUW-Flag-TRF1-FokI D450AGift from R. Greenberg[@bib19]**Software and Algorithms**FijiNIH<https://fiji.sc/>Cell ProfilerBroad Institute<https://cellprofiler.org>Prism 8GraphPad Software<https://www.graphpad.com/>Adobe Photoshop 2020Adobe<https://www.adobe.com/uk/products/photoshop.html>Adobe Illustrator 2020Adobe<https://www.adobe.com/uk/products/illustrator.html>RR core team<https://www.r-project.org/>Bowtie v0.12.9[@bib57]<http://bowtie-bio.sourceforge.net/>Sambamba v0.5.8N/A<http://lomereiter.github.io/sambamba/>MACS v1.4.2[@bib100]<http://liulab.dfci.harvard.edu/MACS/>HOMER v2.8.2[@bib45]<http://homer.ucsd.edu/>Rsamtools R package (version 1.30.0)N/A<http://bioconductor.org/packages/release/bioc/html/Rsamtools.html>DESeq2[@bib69]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>ChIPpeakAnno R package[@bib103]<https://bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html>Geneset Enrichment Analysis (GSEA)[@bib91]<https://www.gsea-msigdb.org/gsea/>Gene Ontology (GO) terms[@bib2]<http://geneontology.org/>GSEABase R package (version 1.40.1)TU Dortmund<http://bioconductor.org/packages/release/bioc/html/GSEABASE.html>The Molecular Signatures Database (MSigDB)[@bib66]<https://www.gsea-msigdb.org/gsea/>Hallmark collection from MSigDB[@bib67]<https://www.gsea-msigdb.org/gsea/>Gencode annotation (version 19)[@bib43]<https://www.gencodegenes.org/>Repbase database (version 22.06)[@bib5]<https://www.girinst.org/repbase/>**Other**Nunc 8-well Lab-Tek II Chamber SlideThermo Fisher ScientificCat\# 154534PKLeica TCS SPE confocal systemLeicaDM2500Olympus IX83 inverted microscope, ScanROlympusN/ABioruptor Pico sonication deviceDiagenodeCat\# B010600102100 Bioanalyzer InstrumentAgilentCat\# G2939BA

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources, reagents, data or code should be directed to and will be fulfilled by the Lead Contact, Travis H. Stracker (<travis.stracker@nih.gov>).

### Materials Availability {#sec4.2.2}

Materials generated in this study are available upon request from the Lead Contact.

### Data and Code Availability {#sec4.2.3}

The accession number for the datasets reported in this paper (ATAC-seq (U-2-OS and HeLa LT), H3.3 ChIP-seq (U-2-OS) and RNA-seq (U-2-OS)) are GEO: [GSE131023](ncbi-geo:GSE131023){#interref310}. <https://www.ncbi.nlm.nih.gov/geo/> The computer code generated during the current study is available on reasonable request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

Human cell lines used in this study are reported in the [Key Resources Table](#sec4.1){ref-type="sec"}. Cells were grown in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Sigma-Aldrich) and penicillin--streptomycin at 37°C in a 5% CO2 incubator. Knockout ΔTLK1 U-2-OS and HeLa LT cell lines were generated using CRISPR/Cas9 genome editing. Guide RNA sequence targeting human TLK1 exon 10 was cloned into the plasmid pX330-CRISPR-Cas9-SV40prom-EGFP ([@bib21]) after digestion with BbsI (NEB). Cells were transfected using Lipofectamine 2000 (Thermo Fisher Scientific) with the corresponding pX330-CRISPR-Cas9-SV40prom-EGFP plasmid and 48 hours following transfection, single cells positive for GFP were FACS-sorted (BD FACSAria III) at a ratio of 1 cell per well in 96 well plates. Single cell clones were expanded and screened by Western Blot for protein levels of TLK1. For lentiviral transductions of shRNA against STING, AD293 producer cells were transfected using PEI (Polysciences Inc.) with 10 μg of pLKO.1-puro-shScramble control (SHC002) or pLKO.1-puro-shSTING (TRCN0000163296) and with lentiviral packaging vectors (2 μg REV, 6 μg RRE and 2 μg VSV-G). Medium was refreshed 8 h after transfection and viral supernatants were collected and filtered through a 0.45 μm filter at approximately 48 and 72 h post-transfection. For infection, cells were overlaid with filtered viral supernatant supplemented with 8 μg/ml Polybrene (Sigma-Aldrich) twice to achieve optimal infection efficiency. Cells were selected with 1 μg/ml of puromycin. U-2-OS cells expressing inducible Cas9 (iCas9) were generated by lentiviral transduction of Edit-R Inducible Cas9 (Dharmacon). Single cell clones were expanded and screened for Cas9 activity.

Method Details {#sec4.4}
--------------

### Drug treatments {#sec4.4.1}

For drug treatment we used: Hydroxyurea (Sigma), Aphidicolin (Calbiochem) at the indicated doses; Roscovitine (Tocris), 50 μM for 5 hours; Mirin (Tocris), 50 μM for 5 hours; BX795 (Selleckchem), 1 μM for 24 hours. For serum starvation experiments, after cell attachment the medium was replaced with low-serum media (0.25% FBS) for serum-starved cells and with fresh media (10% FBS) for asynchronous cells. After 24 h, medium was replaced again (0.25% FBS for serum starved cells; 10% FBS for control cells) until cells were harvested.

### siRNA/crRNA transfections {#sec4.4.2}

For siRNA transfection, cells were transfected with siRNAs (Sigma-Aldrich or Dharmacon) at a final concentration of 100 nM using Lipofectamine RNAiMAX (Thermo Fisher Scientific). Transfections were done on attached cells that had been plated for approximately 18 hours, in media without antibiotics and the transfection mix was prepared in Opti-MEM (Thermo Fisher Scientific). Cells were transfected once and either split for several experiments after 24 hours and harvested after additional 24-72 hours or directly harvested 48-96 hours post-transfection. We used luciferase and GFP targeting or non-targeting siRNA as mock negative controls (siCont). The siRNAs used in this study are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

For crRNA transfection, cells were transfected with crRNA and tracrRNA (1:1 ratio) (Dharmacon) at a final concentration of 50 nM using Lipofectamine RNAiMAX (Thermo Fisher Scientific). Transfection was done in attached cells in media without antibiotics and induction of Cas9 by 1 μg/ml Doxycycline. The transfection mix was prepared in Opti-MEM (Thermo Fisher Scientific). Knockout was assessed 72-120 h after transfection. The crRNAs used in this study are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

### Western blot analysis {#sec4.4.3}

Cells were collected after two cold PBS washes by scraping in 2X SDS Lysis Buffer (4% SDS, 20% Glycerol, 120 mM Tris-Cl pH 6.8, 1x protease (Roche) and phosphatase inhibitors (Sigma-Aldrich)) on ice. Lysates were sonicated at medium-high intensity for 10 minutes in a Bioruptor Standard (Diagenode) placed at 4°C and subsequently boiled for 10 minutes at 90°C. Proteins were quantified using the DC Protein Assay (Bio-Rad), separated by SDS-PAGE and transferred to 0.2 μm pore Nitrocellulose membrane (Amersham Protran; Sigma-Aldrich). Membranes blocked with 5% milk/PBST for 1 h at room temperature and probed with primary antibodies overnight at 4°C. These were detected with appropriate secondary antibodies conjugated to HRP and visualized by ECL-Plus (GE Healthcare).

### Cytokine Detection {#sec4.4.4}

For CXCL10 detection, medium was replaced 48 hours after siRNA transfection and CXCL10 was measured after additional 24 hours in the supernatant of the cells using BD OptEIA Human IP-10 ELISA Kit (BD Bioscience) according to the manufacturer's protocol. For CXCL10 detection on U-2-OS iCas9 cells, medium was replaced 48 hours after crRNA transfection and 24 hours after siRNA transfection and CXL10 was measured after additional 72 hours. ELISA assays were carried out in technical duplicate or triplicate.

### 2′3′-cGAMP ELISA {#sec4.4.5}

HeLa LT and U-2-OS were seeded in 12-well plates, transfected with siRNA and 24 h later cells were split and seeded in 6-well plates. For stimulation with dsDNA90, cells were seeded in 6-well plates and transfected with 4 μg/ml using Lipofectamine 2000 (Thermo Fisher Scientific). 72 h after siRNA treatment and 24 h after dsDNA90 transfection, cells were harvested, counted, washed with PBS, pelleted, and stored at −80°C. To quantify 2′3′-cGAMP levels, pellets corresponding to 250,000 cells (U-2-OS) or 500,000 cells (HeLa LT) were resuspended in 130 μL M-PER buffer (Thermo Fisher Scientific), incubated on ice for 15 min, centrifuged at 16,000 g at 4°C and 2′3′-cGAMP levels were quantified using the 2′3′-cGAMP ELISA Kit (Cayman Chemical) in technical duplicate according to the manufacturer's instructions.

### Immunofluorescence (IF) and IF-FISH {#sec4.4.6}

For IF of chromatin-bound proteins, cells were grown on 8-well Lab Tek II chamber slides (Labclinics) to sub-confluence. For regular IF, cells were grown on Poly-L-Lysine coated coverslips. For chromatin-bound proteins, pre-extraction was performed using cold 0.2% Triton X-100 in 1X PBS on ice for 5 minutes. Cells were fixed for 10 minutes in 4% paraformaldehyde at room temperature and permeabilized for 5 minutes in 0.2% Triton in 1X PBS at room temperature. After two washes in PBS, fixed cells were incubated for 1 h in blocking solution (3% BSA 0.1%Tween/PBS) and stained using primary antibodies diluted 1:250 in blocking solution for 4 h at room temperature in a humid chamber. The secondary antibodies were used at a dilution of 1:500 in blocking solution. Slides were mounted in Vectashield (Vector Laboratories).

For IF-FISH, after standard IF staining with primary and secondary antibody incubations, washes were performed with IF blocking solution. To continue with FISH, slides were fixed again in 4% formaldehyde for 5 min at room temperature, washed in PBS and dehydrated in increasing concentrations of ethanol (70%, 95%, and 100%). The slides were air-dried, incubated with Telomere PNA Probe/Cy3 (Dako-Agilent) or TelC-FITC (PNA Bio) and denatured on an 80°C hot plate for 5-10 minutes. Hybridization took place in the dark for 3-4 hours at room temperature. The slides were subsequently washed in Rinse and pre-heated Wash Solutions (Dako-Agilent) or in wash solution (70% Formamide, 10 mM Tris-HCl pH 7.2) and dehydrated in increasing concentrations of ethanol (70%, 95%, and 100%). Slides were washed in DAPI and mounted in Vectashield (Vector Laboratories).

Confocal fluorescence images were obtained on a Leica DM2500 SPE confocal system. Images were taken with 40x NA 1.15 oil or 63x NA 1.3 oil objectives and the standard LAS-AF software. For high-throughput microscopy (HTM), 24-48 images were automatically acquired from each well with a robotized fluorescence microscopy station (ScanˆR; Olympus) at 40 × magnification and non-saturating conditions. Images were segmented using the DAPI staining to generate masks matching cell nuclei from which the corresponding signals were calculated using an in-house-developed package based on Cell Profiler.

### RNA isolation and RT-qPCR {#sec4.4.7}

Cells were collected after two cold PBS washes by scraping in Tri-Reagent (Sigma-Aldrich). RNA was isolated by chloroform extraction followed by centrifugation, isopropanol precipitation, washing twice in 75% ethanol and resuspension in DEPC-treated water. Nucleic acid quantification was performed with a Nanodrop 8000 Instrument (Thermo Fisher Scientific). Reverse transcription reaction was carried out using High Capacity cDNA Reverse Transcription Kit (ABI), following the manufacturer's instructions, in a reaction volume of 20 μL and with Random primers contained in the kit. cDNA was stored at −20°C. For the detection on Telomeric repeat-containing RNA (TERRA), a first strand cDNA synthesis was first performed with the TERRA-specific RT-primer 5′-CCCTAACCCTAACCCTAACCCTAACCCTAA-3′ [@bib105] and a housekeeping gene-specific primer (Reverse) was included in the same reaction for normalization purposes. The reaction was carried out at 55°C in the presence of RNA inhibitor SUPERase IN (Thermo Fisher Scientific) using the SuperScript III RT (Thermo Fisher Scientific). qPCR was performed using the comparative CT method and a Step-One-Plus Real-Time PCR Instrument (Applied Biosystems). SYBR Green reactions were carried out in technical duplicate or triplicate in a final volume of 10 μl. For SYBR Green 1X SYBR Green PCR Master Mix (no. 4364344; ABI) or 1X SYBR Select Master Mix (no. 4472908; ABI), forward and reverse primer (Sigma; 100-500 nM each) and 25 ng of template were used. Thermocycling parameters used were: 95°C 20 s; 40 cycles 95°C 3 s, 60°C 30 s; melting curve. The 2*−ddCT* method was used for the analysis of the amplification products. Primer pairs used are indicated in [Table S6](#mmc7){ref-type="supplementary-material"}.

### ATAC-seq and -qPCR {#sec4.4.8}

The Assay for Transposase-Accessible Chromatin (ATAC) protocol was adapted from [@bib10]. U-2-OS or HeLa LT cells were transfected in biological duplicate with siRNAs (siCont, siTLK1, siTLK2, siTLK1+2 for U-2-OS, and siCont, siTLK2 for HeLa LT WT and ΔTLK1) and 48 hours post-transfection were collected by trypsinization and counted. 50 000 cells for U-2-OS or 75 000 cells for HeLa LT were resuspended in 50 μL of cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% (v/v) Igepal CA-630) for nuclei preparation and treated with Nextera Tn5 Transposase (Nextera DNA Library Preparation Kit, Illumina) at 37°C for 30 min. DNA was first purified using MinElute PCR Purification Kit (QIAGEN). Samples were amplified by PCR using NEBNext High-Fidelity 2x PCR Master Mix (NEB) using PCR primers Ad1_noMX and Ad2_Barcode (Sigma-Aldrich, see [Table S6](#mmc1){ref-type="supplementary-material"}; [@bib10]) for 5 initial cycles (1 cycle: 5 min 72°C, 30 s 98°C; 5 cycles: 10 s 98°C, 30 s 63°C, 1 min 72°C). A qPCR side reaction was run on a tenth of the previous 5-cycle sample in order to determine the appropriate number of PCR cycles (N) and be able to stop amplification prior to saturation, in the presence of SYBR Green in an Applied Biosystems 7900HT Fast Real-Time PCR System (1 cycle: 30 s 98°C; 20 cycles: 10 s 98°C, 30 s 63°C, 1 min 72°C). Then, the 5-cycle sample was run for an additional N = 6 cycles, so the library had been amplified for a total of 11 cycles. Amplified libraries were purified using PureLink PCR Purification Kit (Thermo Fisher Scientific). The quality of purified libraries was assessed using a Bioanalyzer High-Sensitivity DNA Analysis kit (Agilent) where fragment size showed a periodical distribution of approximately 150-300-600-1200 bp. For ATAC-seq, an equimolar pool was generated and the pool was sequenced in 2 lanes 50 nt paired-end in an Illumina HiSeq2500 (Illumina). ATAC-qPCR was performed with the primers indicated on [Table S6](#mmc7){ref-type="supplementary-material"} on a 1:20 dilution of the eluted DNA after library amplification.

For ATAC-seq analysis, paired end reads of length 50 bp were aligned to the human genome version hg19 using bowtie v0.12.9 ([@bib57]) with default parameters except for n = 1 to limit the maximum number of mismatches in the seed and m = 1 to report the best possible alignment for a given read. Alignments were sorted and indexed using Sambamba v0.5.8 (<http://lomereiter.github.io/sambamba/>). Duplicated reads were removed using Sambamba. Peaks were called with MACS v1.4.2 ([@bib100]) for each sample without any control. All parameters were left as default except for read length. Peaks were annotated with the HOMER v2.8.2 ([@bib45]) software with the hg19 annotations. Consensus peaks were defined as the union of all peaks from all biological samples. For each sample, the number of reads per peak was computed using the countBam function from the Rsamtools R package (version 1.30.0, <http://bioconductor.org/packages/release/bioc/html/Rsamtools.htm>). Differential accessibility was computed using DESeq2 ([@bib69]) with replicate as covariate. For ATAC-seq overlap with epigenetic marks, epigenetic information was downloaded from the Encode website ([@bib43]) (H3K9me3 \[ENCFF001VDL\]). Consensus peaks were classified according to their overlap with each epigenetic track \[minimum overlap length 100bp\]. P values were computed with a Mann-Whitney test as implemented in the function wilcox.test in R [@bib104]. For ATAC-seq FC correlation between replication time and methylation marks, the Repliseq track (wgEncodeUwRepliSeqNhekWaveSignalRep1.bigWig) was downloaded from the Encode website in Bigwig format. H3K36me3 and H3K9me3 corresponding to the U-2-OS cell line were also downloaded in Bigwig format from the same repository. Mean normalized signal was computed for 10kb bins along the genome. Spearman correlations coefficients were computed with the cor function in R. For [Figure S1](#mmc1){ref-type="supplementary-material"}D, Repliseq scores were binned in 25 quantiles. For ATAC-seq FC overlap with colors of chromatin, tracks were downloaded from Encode (wgEncodeAwgSegmentation ChromhmmHelas3.bed) corresponding to the ChromHMM algorithm ([@bib31]) in the HeLa-S3 cell line. Peaks were classified to the color with larger overlapping segment. For better visualization, colors were collapsed to 10 classes as follows: Active Promoter = {Tss, TssF}, Promoter Flanking = {PromF}, Inactive Promoter = {PromP}, Candidate Strong enhancer = {Enh, EnhF}, Candidate Weak enhancer/DNase = {EnhWF, EnhW, DnaseU, DnaseD, FaireW}, Distal CTCF/CandidateInsulator = {CtcfO, Ct*cf.*}, Transcription associated = {Gen5, Elon, ElonW, Gen3, Pol2, H4K20}, Low activity proximal to active states = {Low}, Polycomb repressed = {ReprD, Repr, ReprW}, Heterochromatin/Repetitive/Copy Number Variation = {Quies, Art}.

### Chromatin immunoprecipitation (ChIP) {#sec4.4.9}

U-2-OS cells were transfected in biological duplicate with siRNAs (siCont and siTLK1+2) and 48 hours post-transfection were harvested by trypsinization. Cells were crosslinked with 1% formaldehyde in DMEM for 10 min at room temperature and quenched with glycine at a final concentration of 125 mM. Cells were washed with PBS, pelleted by centrifugation and dry pellets were snap frozen. For nuclear extract preparation, pelleted cells were thawed on ice, resuspended in cold Swelling buffer (25 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 1x protease (Roche) and phosphatase inhibitors (Sigma-Aldrich)) for 10 min and passed through a douncer 50 times. Nuclei were pelleted by centrifugation at 3000 g for 5 min at 4°C, and resuspended in 300 μl of 1% SDS in ChIP buffer (10 mM Tris-HCl pH 7.5,150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 0.5 mM DTT, 1x protease (Roche) and phosphatase inhibitors (Sigma-Aldrich)). The extracts were incubated for 15 min on ice and sonicated in a Bioruptor Pico sonication device (Diagenode) for 30 cycles 30'' on/30'' off. Chromatin was cleared by centrifugation at top speed 15 min at 4°C and checked for size after a phenol/chloroform extraction by an agarose gel and by a Bioanalyzer DNA HS Chip (Agilent; Integrated Sciences) so chromatin fragments have a size of 200 bp on average. For H3.3 (Millipore 09-838) and H3K9me3 (Abcam ab8898) ChIP, 5 μg of total chromatin was diluted 1:10 in ChIP buffer and incubated with 1 μg of antibody on rotation at 4°C overnight. 50 μl of prewashed Dynabeads Protein G (Thermo Fisher Scientific) were added on rotation for 2h at 4°C. Beads were washed with Low Salt buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1% Triton X-100, 1x protease (Roche) and phosphatase inhibitors (Sigma-Aldrich)), High Salt buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 1% Triton X-100, 1x protease (Roche) and phosphatase inhibitors (Sigma-Aldrich)) and eluted by incubating in a thermomixer with Elution buffer (1% SDS, 100 mM NaHCO3) for 30 min at 65°C and 1000rpm. Samples were reverse-crosslinked by incubating at 65°C overnight and incubated with Proteinase K for 1h at 45°C. Chipped DNA was purified using the MinElute PCR Purification Kit (QIAGEN) and eluted in 40 μl. Purified ChIP DNA was used for library generation using the NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB) following manufacturer's instructions. Each of the libraries was labeled by a specific barcode provided in NEBNext Multiplex Oligos for Illumina (Index Primers Set 1 and 2) (NEB) and amplified 9-13 cycles (depending on initial material amount) by PCR in the presence of SYBR Green in order to obtain an optimal yield. Libraries were quantified using DNA HS Qubit (Thermo Fisher Scientific) and size measured by a 2100 Bioanalyzer Instrument (Agilent) and a DNA HS Chip (Integrated Sciences). An equimolar pool was sequenced in 2 lanes 50 nt single read in an Illumina HiSeq2500 (Illumina). Libraries were also used as a template for qPCR using the primers corresponding to telomeric repeats (Tel) listed in [Table S6](#mmc7){ref-type="supplementary-material"}.

For ChIP-seq analysis, single end reads of 50 bp length were aligned to the hg19 human genome version using Bowtie v0.12.9 ([@bib57]) with default parameters. Alignments were sorted and indexed using Sambamba v0.5.8 (<http://lomereiter.github.io/sambamba/>). Duplicated reads were removed using Sambamba. Peaks were called with MACS v1.4.2 ([@bib100]) for each sample with the corresponding input as control. All parameters were left as default except for read length. Peaks were annotated with the HOMER v2.8.2 ([@bib45]) software with the hg19 annotations. Consensus peaks were defined as the union of all peaks from all samples. For each sample, the number of reads per peak was computed using the countBam function from the Rsamtools R package (version 1.30.0, <http://bioconductor.org/packages/release/bioc/html/Rsamtools.htm>). Differential binding was computed using DESeq2 ([@bib69]) with replicate as covariate. Normalized densities for peaks were computed using the annotatePeaks function from the HOMER suite. Densities were plotted using the feature AlignedDistribution function from the ChIPpeakAnno R package ([@bib103]).

### RNA-seq {#sec4.4.10}

U-2-OS cells were transfected in biological duplicate with siRNAs (siCont, siTLK1, siTLK2, siTLK1+2) and 48 hours post-transfection were washed twice with cold PBS and collected by scraping in Tri-Reagent (Sigma-Aldrich). RNA was isolated using the PureLink RNA Mini Kit (Thermo Fisher Scientific) following the manufacturer's instructions for TRIzol Plus Total Transcriptome Isolation. Briefly, chloroform extraction followed by centrifugation resulted in a colorless upper aqueous phase that was mixed 1:1 with 100% ethanol. Sample containing RNA in 50% ethanol was bound to the spin cartridge, washed twice with Wash Buffer II and eluted in RNase-free water.

To avoid limiting our analysis in mRNA polyA+, we performed enrichment of whole transcriptome RNA by depleting ribosomal RNA (rRNA) species. Purified RNA samples were first quantified for integrity, size, and purity by a 2100 Bioanalyzer Instrument (Agilent) and an RNA 6000 Nano Chip (Integrated Sciences). 2 μg of total RNA were processed for rRNA depletion by Ribozero Gold rRNA Removal kit (Human/Mouse/Rat) (Illumina) following manufacturer's instructions. rRNA-free RNA was subsequently fragmented and cDNA generated by NEBNext RNA First Strand Synthesis Module (NEB) and NEBNext mRNA Second Strand Synthesis Module (NEB). Resulting cDNA was purified, quantified, and used for library generation for Next Generation Sequencing using the NEBNext Ultra II DNA library prep for Illumina (NEB). Each of the libraries was labeled by a specific barcode provided in NEBNext Multiplex Oligos for Illumina (Index Primers Set 1) (NEB) and amplified 7 cycles by PCR in the presence of SYBR Green in order to obtain an optimal yield. Libraries were quantified using DNA HS Qubit (Thermo Fisher Scientific) and size measured by a 2100 Bioanalyzer Instrument (Agilent) and a DNA HS Chip (Integrated Sciences). An equimolar pool was generated with the eight libraries and the pool was sequenced in 2 lanes 50 nt single read in an Illumina HiSeq2500 (Illumina).

Single end reads of length 50 bp were aligned to the human genome version hg19 using bowtie v0.12.9 ([@bib57]) with default parameters. Alignments were sorted and indexed using Sambamba v0.5.8 (<http://lomereiter.github.io/sambamba/>). Gene differential expression was performed using DESeq2 ([@bib69]) with replicates as covariate. Pathway enrichment was assessed through the preranked version of Geneset Enrichment Analysis (GSEA)([@bib91]). GSEA was applied to the ranking defined by the log2 Fold Change of the differential expression analysis using DESeq2. Genesets for analyses were from the Gene Ontology (GO) terms ([@bib2]) as collected in the GSEABase R package (version 1.40.1), or from the Hallmark collection ([@bib67]) after retrieval from the MsigDB ([@bib66]). Classification in coding and noncoding gene classes was performed according to the Gencode annotation version 19 ([@bib43]). For Repeat Masker analysis, sequences from repeat elements in the human Repbase database version 22.06 ([@bib5]) were downloaded. Reads were aligned using bowtie with parameters --best and -k = 1. Fold changes were computed between siTLK1+2 and siCont samples using normalized reads values of those repeat sequences that had at least 100 raw reads.

### C-circle assay {#sec4.4.11}

The C-circle assay protocol was adapted from [@bib47]. Genomic DNA from 200 000 cells was extracted by incubating cells with 50 μl of QCP lysis buffer (50 mM KCl, 10 mM Tris-HCl pH 8.5, 2 mM MgCl2, 0.5% IGEPAL CA-630, 0.5% Tween-20) and 3 μl of QIAGEN protease shaking at 1400 rpm at 56°C for 1 hour. The QIAGEN protease was inactivated by incubating the samples at 70°C for 20 min. DNA concentration was measured by fluorimetry using the Qubit dsDNA HS Assay (Thermo Fisher Scientific). Samples purified from U-2-OS and HeLa LT cells were pre-diluted in QCP lysis buffer at 5 ng/μl and 30 ng/μl, respectively. 5 or 30 ng of DNA were diluted to 10 μl in 10mM Tris-HCl pH 7.6 and mixed with 9.25 μl of Rolling Circle Master Mix (RCMM) (8.65mM DTT, 2.16X 10X ϕ29 Buffer, 8.65ug/mL BSA, 0.216% Tween-20 and 2.16mM of each dATP, dCTP, dGTP and dTTP) and 0.75 μl of ϕ29 DNA Polymerase (NEB or Thermo Fisher Scientific). Rolling Circle Amplification was performed by incubating samples in a thermocycler at 30°C for 8 hours, polymerase was inactivated at 70°C for 20 min and then kept at 8-10°C. Samples were kept at −20°C. For slot blot detection, samples were diluted with 2x SSC to 200 μl, then slot-blotted onto Nytran SuPerCharge (SPC) nylon blotting membranes (Sigma-Aldrich) under native conditions. After 254 nm UV-C crosslinking, the membrane was hybridized with γ-^32^P labeled Tel-C oligo probe (CCCTAA)~4~ in hybridization buffer (1.5X SSPE, 10% polyethylene glycol (PEG) MW 8000, 7% SDS) for 16 h. Membrane was exposed onto a storage phosphor screen (Molecular Dynamics) and scanned using Typhoon 8600 Variable Mode Imager (Molecular Dynamics). Membrane was stripped in wash solution (0.5X SSC, 0.1% SDS) at 65°C and re-hybridized with γ-^32^P labeled Alu oligo probe for loading control.

### Analysis of TCGA signatures {#sec4.4.12}

TCGA RNA-Seq datasets were downloaded from the legacy archive of the NCI GDC commons database ([@bib37]) and processed separately for each cancer type. Expression measures were expressed in RSEM ([@bib62]) in this TCGA version, which were log2-transformed and quantile normalized. For patients with multiple instances, a single sample chosen at random was kept while the rest were excluded from further analyses. For a number of cancer types there were two different platforms available: Illumina HiSeq 2000 (HiSeq) and Illumina Genome Analyzer (GA); in such cases, duplicated samples across platforms were removed from the GA dataset while the HiSeq instance was kept in the final dataset. Samples whose expression values showed an unusual distribution compared to the rest of samples in their datasets were also excluded (ACC: TCGA-OR-A5L9-01A; HNSC: TCGA-D6-A6ES-01A and TCGA-CV-A45Q-01A; LAML: TCGA-AB-2955-03A, TCGA-AB-2986-03A, TCGA-AB-2816-03A, TCGA-AB-2955-03A, TCGA-AB-2986-03A and TCGA-AB-2816-03A; LIHC: TCGA-DD-A3A6-11A and TCGA-FV-A4ZP-01A; SKCM: TCGA-D3-A2JK-06A; UCEC: TCGA-BS-A0V4-01A; UVM: TCGA-WC-A885-01A; COAD: TCGA-A6-2679-01A and TCGA-AA-A004-01A). For each cancer type, expression matrices were corrected a-priori by platform, source center, and plate id, when suitable. For doing so, a linear model was fitted to the expression values gene wise in which platform and source center were included as fixed effects. Regarding sample's plate id, it was included in the models as a fixed or a random effect depending on the number of levels and sample size available for the cancer type under consideration. In some cases, additional variables were also included in the models in order to preserve signal with biological or clinical relevance (BLCA: diagnosis subtype; BRCA: PAM50 subtype; COAD and STAD: microinstability status; KIRP: tumor type).

Aneuploidy score and Stromal and Leukocyte fraction estimates were obtained from [@bib92]. To estimate chromosomal instability (CIN) we computed signatures with the gene set CIN25 published in [@bib13]. ALT status was taken from [@bib58]. Gene signature scores were computed as the mean of all genes in the signature after scaling the expression matrix gene wise. The global signature was defined as the score associated with the gene signature containing all genes in the expression matrix. Correlation coefficients and p values were computed using the 'pcor.test' function from the ppcor R package ([@bib51]). In order to avoid spurious correlations due to technical and global effects ([@bib11]), partial correlations were computed whenever a gene signature was involved with the global signature as adjusting variable.

For the association between ALT status and signatures, expression matrices for all available TCGA datasets were scaled gene wise and merged. Only those cancer types with more than two ALT+ patients were included in the merged dataset. In order to account for possible technical and global effects, gene signature scores were adjusted by the global signature before plotting ([@bib11]). P values and coefficients of the association between gene expression or gene signatures and ALT status were computed through a linear model with the dataset as covariable. Whenever gene signatures were being tested, the global signature was also included as covariable. The scores associated to stromal fraction, leukocyte fraction, and aneuploidy were transformed using the square root to ensure normality of the data for the linear model. P values were adjusted for multiple comparisons using Benjamini-Hochberg.

Quantification and statistical analysis {#sec4.5}
---------------------------------------

Statistical significance of non-sequencing experiments was determined with the tests stated in the figure legends using PRISM software (GraphPad Software Inc.). All data are from a minimum of two independent experiments. Specific biological replicate numbers (n) for each experiment can be found in the corresponding figure legends. Statistical analysis of ATAC-seq FC were computed with a Mann-Whitney test as implemented in the function wilcox.test in R. Statistical analysis of TCGA datasets is described in detail in the corresponding methods section. Statistically significant differences are labeled with one, two, three or four asterisks if p \< 0.05, p \< 0.01, p \< 0.001 or p \< 0.0001, respectively.
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